Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions

被引:39
作者
Heinisch, M
Gallowitsch, HJ
Mikosch, P
Kresnik, E
Kumnig, G
Gomez, I
Lind, P
Umschaden, HW
Gasser, J
Forsthuber, EP
机构
[1] St Vincents Hosp, Pet Ctr Linz, Dept Nucl Med & Endocrinol, A-4010 Linz, Austria
[2] LKH Klagenfurt, Dept Gynecol & Obstet, Klagenfurt, Austria
关键词
D O I
10.1016/S0960-9776(02)00262-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of our study was a direct comparison of the ability of positron-emission tomography with FDG-PET and of magnetic resonance imaging (MRI) to determine whether breast lesions were benign or malignant and of the two imaging methods capability of depicting eventual multifocal disease. We performed both PET and MRI in 36 patients (40 lesions) who were scheduled for surgery because of suggestive mammographic, sonographic and/or clinical findings. A final histological classification was available for all lesions. Tumour size ranged from 5 to 45 mm (mean 16.7 mm). Sensitivity for lesions, sensitivity for patients, specificity for lesions and specificity for patients were 68.0%, 76.2%, 73.3%, and 73.3% for PET and 92.0%, 95.2%, 73.3%, and 73.3% for MRI, respectively. MRI was more sensitive than FDG-PET in disclosing malignant breast tumours and was also more accurate than FDG-PET in the assessment of multifocal disease. The lower sensitivity of FDG-PET than of MRI seems to be due to difficulties in reliable imaging of carcinomas smaller than 10mm and of lobular carcinomas. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:17 / 22
页数:6
相关论文
共 29 条
[1]  
Avril N, 1997, J NUCL MED, V38, P1186
[2]   Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose [J].
Avril, N ;
Dose, J ;
Janicke, F ;
Bense, S ;
Ziegler, S ;
Laubenbacher, C ;
Romer, W ;
Pache, H ;
Herz, M ;
Allgayer, B ;
Nathrath, W ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1848-1857
[3]   F-18FDG uptake in breast infection and inflammation [J].
Bakheet, SMB ;
Powe, J ;
Kandil, A ;
Ezzat, A ;
Rostom, A ;
Amartey, J .
CLINICAL NUCLEAR MEDICINE, 2000, 25 (02) :100-103
[4]  
Bjurstam N, 1997, CANCER, V80, P2091, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2091::AID-CNCR8>3.0.CO
[5]  
2-#
[6]   Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer:: initial experience [J].
Brix, G ;
Henze, M ;
Knopp, MV ;
Lucht, R ;
Doll, J ;
Junkermann, H ;
Hawighorst, H ;
Haberkorn, U .
EUROPEAN RADIOLOGY, 2001, 11 (10) :2058-2070
[7]  
BROWN RS, 1993, CANCER, V72, P2979, DOI 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO
[8]  
2-X
[9]  
Brown RS, 1996, J NUCL MED, V37, P1042
[10]   Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer:: a preliminary observation [J].
Crippa, F ;
Seregni, E ;
Agresti, R ;
Chiesa, C ;
Pascali, C ;
Bogni, A ;
Decise, D ;
De Sanctis, V ;
Greco, M ;
Daidone, MG ;
Bombardieri, E .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (10) :1429-1434